Variables | SEED-BT (n = 151) | RP (n = 151) | P |
---|---|---|---|
Age, median (range), years | 69 (48–82) | 68 (53–79) | 0.214 |
PSA at diagnosis, median (range), ng/mL | 8.3 (2.6–18.0) | 6.3 (2.9–19.8) | 0.253 |
Clinical stage, number (%) | Â | Â | 1.000 |
 T1c | 84 (55.6%) | 84 (55.6%) |  |
 T2a–c | 67 (44.4%) | 67 (44.4%) |  |
Gleason grade, number (%) | Â | Â | 0.472 |
 1 | 30 (19.9%) | 23 (15.2%) |  |
 2 | 82 (54.3%) | 82 (54.3%) |  |
 3 | 39 (25.8%) | 46 (30.5%) |  |
Positive biopsy core rate, number (%) | Â | Â | 0.552 |
  < 34% | 92 (60.9%) | 97 (64.2%) |  |
  ≥ 34% | 59 (39.1%) | 54 (35.8%) |  |
Favorable intermediate-risk, number (%) | 74 (49.0%) | 77 (51.0%) | 0.730 |
Follow-up, median (range), mos | 93 (1–153) | 92 (11–153) | 0.434 |
Neoadjuvant hormonal therapy yes, number (%) | 46 (30.5%) | 8 (5.2%) | – |
Adjuvant hormonal therapy yes, number (%) | 0 (0.0%) | 0 (0.0%) | – |
Salvage radiotherapy, number (%) | – | 23 (15.2%) | – |
Positive surgical margin, number (%) | – | 0 (0.0%) | – |
 Open surgery (n = 79), number (%) |  | 0 (0.0%) |  |
 Laparoscopic surgery (n = 72), number (%) |  | 0 (0.0%) |  |
Combined EBRT, number (%) | 39 (25.8%) | – | – |
 Favorable intermediate-risk | 8 (7.9%) |  |  |
 Unfavorable intermediate-risk | 31 (27.1%) |  |  |
Prostate D90 at 1Â month, Gy | Â | Â | Â |
 SEED-BT alone | 185.3 (141.0–225.4) | – |  |
 Combined EBRT | 121.2 (99.4–180.8) | – |  |
Prostate V100 at 1Â month, Gy | Â | Â | Â |
 SEED-BT alone | 98.0% (80.1–100) | – |  |
 Combined EBRT | 96.4% (90.0–99.3) | – |  |
Prostate V150 at 1Â month, Gy | Â | Â | Â |
 SEED-BT alone | 68.2% (23.4–97.3) | – |  |
 Combined EBRT | 62.2% (43.6–84.9) | – |  |
BED, Gy2 | 204.8 (147.9.–284.1) | – |  |